Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $196.93M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.82M
Average 0.36M
TRDA Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Entrada Therapeutics, Inc.NASDAQ: TRDA
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures dips below year-ago levels
Q1 FY2026 capital expenditures of $44K (cash outflow) fell 96.2% year over year, behind the +101.7% change in trailing-twelve-month capital expenditures. Over 3 fiscal years it compounded at -28.8% a year.
Context
- Capital expenditures amounted to 4.1% of revenue in FY2025, up 2.6 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -96.2% toward the trailing-twelve-month pace of +101.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (1.04M) USD
- Year-over-year change
- +67.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.04M) | +67.0% |
| FY2024 | 2024-12-31 | (3.16M) | +43.7% |
| FY2023 | 2023-12-31 | (5.61M) | -94.5% |
| FY2022 | 2022-12-31 | (2.89M) | +37.0% |
| FY2021 | 2021-12-31 | (4.58M) | — |
Capital Expenditures vs competitors
How TRDA compares with its peers on the latest reported figures
- TRDA's LTM Mar 2026 capital expenditures of $59K is the 8th largest of the 11 companies compared; the peer median is $307.33K.
- Its year-over-year change of +101.7% is the 3rd highest of 8, against a peer median of -14.8%.
- Capital expenditures amounts to 1.0% of revenue for TRDA, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.33M | +958.6% | -4.7% | — | |
| LTM Mar 2026 | $1.95M | -4.2% | +1.4% | 5.3% | |
| LTM Mar 2026 | $831K | -41.0% | -5.5% | 41.2% | |
| LTM Mar 2026 | $783K | -14.8% | +13.7% | 0.4% | |
| LTM Mar 2026 | $318.66K | -41.5% | -69.0% | 0.7% | |
| LTM Mar 2026 | $296K | -62.3% | -57.9% | — | |
| LTM Mar 2026 | $213.21K | +278.4% | -42.4% | — | |
| LTM Mar 2026 | $59K | +101.7% | -28.8% | 1.0% | |
| LTM Mar 2026 | $3K | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding TRDA) | $307.33K | -14.8% | -5.5% | 3.0% | |
Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.16M) | (94.62M) | (6.69M) | 65.63M | (143.75M) |
| Depreciation & Amortization | 1.12M | 1.9M | 2.84M | 3.77M | 4.1M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.53M | 9.9M | 13.11M | 17.92M | 19.61M |
| Change in Working Capital | (3.42M) | (11.11M) | 136.32M | (118.85M) | (4.8M) |
| Accounts Receivables | 0 | 0 | 0 | 2.2M | 2.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (715K) | 5.29M | (2.81M) | 991K | (1.8M) |
| Other Working Capital | (2.71M) | (16.4M) | 139.12M | (122.04M) | (5.5M) |
| Other Non-Cash Items | 74K | 151K | (5.78M) | (10.02M) | (3.67M) |
| Operating Cash Flow | (50.86M) | (93.79M) | 139.8M | (41.56M) | (128.51M) |
| Capital Expenditures | (4.58M) | (2.89M) | (5.61M) | (3.16M) | (1.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (221.98M) | (407.21M) | (437.72M) | (141.61M) |
| Sales of Investments | 0 | 76.21M | 274.43M | 413.08M | 259.46M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (4.58M) | (148.65M) | (138.4M) | (27.8M) | 116.81M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 190.69M | 479K | 19.41M | 99.61M | 887K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 939K | 0 | 1.63M | 3.36M | 0 |
| Financing Cash Flow | 307.46M | 479K | 21.04M | 102.96M | 887K |
| Effect of Forex Changes | 0 | (3.95M) | 0 | 0 | 0 |
| Net Change in Cash | 252.02M | (245.91M) | 22.45M | 33.61M | (10.82M) |
| Free Cash Flow | (55.44M) | (96.67M) | 134.19M | (44.72M) | (129.55M) |
Entrada Therapeutics, Inc.
NASDAQ:TRDA
Intrinsic Alpha fair value
Locked
Current Price
$5.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.